| Editor's Note: Fierce Life Sci's weekly digest will be taking a publication break next week, July 5, for the U.S. Independence Day holiday. We'll be back in your inboxes July 12. |
|
September 30- October 1, 2024| Boston, MA The Fierce New Product Planning Summit is the only conference focused on how life science professionals make informed, value-based, data-driven decisions about pipeline products. Experts gather annually to discuss resource utilization and key questions for commercial success. Stay Updated! 
|
|
| By Gabrielle Masson It’s the end of an era—eFFECTOR Therapeutics’ era to be exact. The oncology biotech has laid off staff as it plans to wind down, according to a June 24 release. |
|
|
|
By Kevin Dunleavy A month after Eli Lilly revealed a $5.3 billion investment to increase its manufacturing capacity of its diabetes and obesity treatments, Novo Nordisk has answered. The Danish drugmaker said it will spend $4.1 billion to construct a second fill-finish plant at its sprawling campus in Clayton, North Carolina. |
By James Waldron The past couple of years have seen Big Pharmas whip out their wallets to place high-stake bets in the red-hot races for antibody-drug conjugates, radiopharmaceuticals and obesity drugs, to name a few. We wanted to take another look at some of the deals that have kept our attention. |
By Kevin Dunleavy After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. And what better way to do it than to win a major contract in your rival’s home country? The U.K. government has selected Pfizer to supply 5 million doses of its RSV shot Abrysvo over the next two years. |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save $500 with Early Bird Rate Today! 
|
|
By Annalee Armstrong After a full data analysis, Altimmune is heralding phase 2 obesity data for pemvidutide as “best-in-class” for spurring weight loss while preserving lean mass. |
By Conor Hale Using a version of OpenAI’s GPT-4 program, the AI quickly combed through doctors' notes and identified patients with heart failure who met study criteria. |
By Fraiser Kansteiner A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established formulation of carbidopa and levodopa. |
By Kevin Dunleavy The FDA has expanded the label for Sarepta's Elevidys to all Duchenne muscular dystrophy patients ages 4 and older. It’s a major boost for the first gene therapy to treat the inherited disorder, which received an accelerated approval a year ago—nearly to the date—but only for ambulatory boys ages 4 to 5. |
By Helen Floersh GLP-1 drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy work to address obesity—as long as a patient keeps taking them. Harith Rajagopalan, M.D., Ph.D. thinks his company, Fractyl Health, may have the answer. |
By Gabrielle Masson The Biotechnology Innovation Organization’s CEO John Crowley isn’t shying away from the tough tasks. With only a little more than three months at the helm of the world’s largest biotech advocacy group, the leader has already implemented a wide-scale restructure and taken a firm stance with Congress regarding U.S. biosecurity. |
By Andrea Park Data released earlier this month showed that across nearly 600 cancer patient groups, Roche was rated as having the best reputation among pharmas. Now, PatientView has offered an even deeper dive into those findings, breaking out patient sentiments by several cancer types. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Fierce Healthcare’s Anastassia Gliadkovskaya chats with Carrot Fertility’s chief product officer, James Wong, about his personal family-building story and the challenges faced by the LGBTQ+ community when building families. |
|
|---|
|
|
|
Wednesday, July 10, 2024 | 11am ET / 8am PT AI capabilities are now pushing into GxP regulated business functions. Join us as a panel of experts takes a deep dive into emerging practices to demonstrate how Life Sciences companies can integrate AI-based solutions into GxP functions responsibly. Register here today. 
|
|
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper The Role of Environmental Monitoring in a Contamination Control Strategy Sponsored by: ThermoFisher Scientific |
Whitepaper This study delved into the manufacturing costs of the three mRNA capping methods. It involved discussions with 30 subject matter experts engaged in mRNA therapeutic development across various companies in the US and the EU. Sponsored by: TriLink |
Whitepaper An insider’s workbook filled with practical tips and tools for designing and scaling a global patient support program. Sponsored by: Harte Hanks |
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Research Learn how a Top-10 Pharma company automated the extraction of oncology efficacy endpoints from scientific literature with high precision and recall using a combination of AI technologies. Sponsored by: IQVIA |
eBook This eBook offers insights for business leaders looking to do more with reduced budgets by using the power of SmartIQ’s true forms automation to eliminate the need to print, sign, and scan/mail physical documents, increase operational efficiency, and reduce disparate systems. Sponsored by: SmartComms LLC |
Whitepaper Virtual care programs represent a compelling opportunity for decision makers in life sciences companies to drive growth, innovation, and value creation. Download now to learn more. Sponsored by: Wheel |
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Sponsored by: Lonza |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
.png)
